However, some transporters, including OATP1B1/3 and OAT3, demonstrated inhibition following treatment with GLP-1 RAs and a dual GLP-1/GIP RA in vitro, suggesting that the assessment of transporter-mediated DDI by GLP-1 RAs may be necessary (Table 3)
Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorption
Longevity Medicine Education Series This article is part of the HormoneSynergy Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging
Most patients increase their dose every four weeks, moving from 2.5mg through 5mg, 7.5mg, 10mg, and potentially up to 15mg depending on response and tolerance